Alexion's Klygefa clears US and EU for weekly self-injected gMG therapy
AstraZeneca's rare disease arm Alexion just landed US and EU approvals for Klygefa (gefurulimab), a once-weekly subcutaneous C5 inhibitor for generalised myasthenia gravis. Japan has cleared it too. It slots into a $6.5 billion franchise alongside Soliris and Ultomiris, and hands patients an injection they can give themselves.
- 2 sources report it: pharmaphorum.com, fiercepharma.com.
- The source published it on Nov 16, 2026 at 3:53 AM.
Nothing open. Every check passed.
Alexion picked up regulatory green lights in both the US and the EU for Klygefa, a generalised myasthenia gravis therapy, with Japan also approving the drug. Klygefa (gefurulimab) is a dual-binding nanobody C5 inhibitor delivered by subcutaneous injection. Patients can administer it once a week themselves using an autoinjector or prefilled syringe, skipping the regular trips to infusion clinics that intravenous treatments demand.
The new entrant joins Alexion's C5 inhibitor line-up of intravenous Soliris (eculizumab) and Ultomiris (ravulizumab), a franchise AstraZeneca values at $6.5 billion. Timing matters: Soliris has begun losing patent protection, with sales falling by a quarter, now at roughly $1 billion in the first nine months of the year as biosimilars bite. The brand once pulled in $4 billion a year at its peak. Longer-acting Ultomiris, infused every eight weeks instead of every two, is still growing, up 16%, now at $4 billion over the same period, with patent cover running into the mid-2030s.
Klygefa walks into a crowded field. Argenx's Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) and UCB's Rystiggo (rozanolixizumab) are already weekly subcutaneous options in the US and EU, but both are FcRn blockers with a different mechanism and must be given by a physician. UCB's Zilbrysq (zilucoplan) is the direct rival in the injectable C5 inhibitor lane, a once-daily shot patients self-administer. AstraZeneca has forecast peak sales of between $1 billion and $3 billion for Klygefa, though some analysts are less bullish given how many treatments now crowd gMG, a rare autoimmune disorder marked by severe muscle weakness.
Klygefa works two ways at once: it blocks the C5 protein to curb neuromuscular damage in gMG, and binds serum albumin to stretch out its half-life. In the PREVAIL trial it produced a statistically significant improvement from baseline in gMG symptoms on the MG-ADL scale over 26 weeks. Unlike Soliris and Ultomiris, which were built for a broad range of complement-mediated diseases, AstraZeneca and Alexion aimed Klygefa squarely at gMG, partly to avoid cannibalising Ultomiris and oral Factor D inhibitor Voydeya (danicopan) in core indications such as paroxysmal nocturnal haemoglobinuria and haemolytic uraemic syndrome.
The Myasthenia Gravis Foundation of America welcomed the approval. CEO Samantha Masterson said expanding the range of options is fundamental to improving lives, because no two patients experience gMG the same way. She added that the foundation backs the new possibilities the approval opens for people seeking more independence and greater control over how they receive treatment.
TopicsAstraZeneca · Alexion · Klygefa · Soliris · Ultomiris · Argenx · UCB · Myasthenia Gravis Foundation of America
Written by AI from verified reporting.

